IBDEI14T ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,20274,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,20275,0)
 ;;=281.1^^131^1286^124
 ;;^UTILITY(U,$J,358.3,20275,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20275,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,20275,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,20275,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,20276,0)
 ;;=286.7^^131^1286^54
 ;;^UTILITY(U,$J,358.3,20276,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20276,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,20276,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,20276,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,20277,0)
 ;;=289.9^^131^1286^120
 ;;^UTILITY(U,$J,358.3,20277,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20277,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,20277,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,20277,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,20278,0)
 ;;=451.9^^131^1286^121
 ;;^UTILITY(U,$J,358.3,20278,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20278,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,20278,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,20278,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,20279,0)
 ;;=446.6^^131^1286^122
 ;;^UTILITY(U,$J,358.3,20279,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20279,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,20279,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(Ttp)
 ;;^UTILITY(U,$J,358.3,20279,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,20280,0)
 ;;=286.4^^131^1286^125
 ;;^UTILITY(U,$J,358.3,20280,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20280,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,20280,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,20280,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,20281,0)
 ;;=204.00^^131^1286^1
 ;;^UTILITY(U,$J,358.3,20281,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20281,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,20281,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,20281,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,20282,0)
 ;;=204.01^^131^1286^3
 ;;^UTILITY(U,$J,358.3,20282,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20282,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,20282,1,5,0)
 ;;=5^ALL,In Remission
 ;;^UTILITY(U,$J,358.3,20282,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,20283,0)
 ;;=204.10^^131^1286^16
 ;;^UTILITY(U,$J,358.3,20283,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20283,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,20283,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,20283,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,20284,0)
 ;;=204.11^^131^1286^18
 ;;^UTILITY(U,$J,358.3,20284,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20284,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,20284,1,5,0)
 ;;=5^CLL,In Remission
 ;;^UTILITY(U,$J,358.3,20284,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,20285,0)
 ;;=201.90^^131^1286^83
 ;;^UTILITY(U,$J,358.3,20285,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20285,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,20285,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,20285,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,20286,0)
 ;;=785.6^^131^1286^89
 ;;^UTILITY(U,$J,358.3,20286,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20286,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,20286,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,20286,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,20287,0)
 ;;=200.20^^131^1286^90
 ;;^UTILITY(U,$J,358.3,20287,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,20287,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,20287,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,20287,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,20288,0)
 ;;=202.00^^131^1286^92
 ;;^UTILITY(U,$J,358.3,20288,1,0)
 ;;=^358.31IA^5^2
